Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do http://www.frost.com/c/10024/home.do - Healthcare Research Frost & Sullivan Innovations in Neuromodulation, Connected Health, Microneedles, Telemedicine, and Advanced Orthopedic Implants http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1A-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-1A-00-00 The latest edition of Medical Device TOE profiles diverse innovations from the advanced medical technology ecosystem. These include a neuromodulation system to manage chronic pain and muscular disorders, a remote patient monitoring system to manage heart conditions, and a compact proton beam therapy that promises more accurate radiation therapy in a cost-effective manner. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Remote patient monitoring, neuromodulation, proton beam therapy, orthopedic implants Fri, 16 Feb 2018 00:00:00 +0000 Leading Technology Innovations Across the Global Biotech Landscape http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6D-00-00 This edition of the Genetic Technology TOE depicts the current landscape and new life sciences trends across biotechnologies. Innovations profiled are antibody drug conjugates, autosampling platforms, advances in UV light to fight influenza virus, and novel liquid biopsy tests. Clinical trials analysis for Phase 3 studies in Hodgkin s disease is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Antibody drug conjugate platform, cancer management, Hodgkin s disease, autosampling platform, protein stability, aggregation testing, UV light, Influenza virus, liquid biopsy Fri, 16 Feb 2018 00:00:00 +0000 Poland s New Business Models in Medical Imaging, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MBF9-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MBF9-01-00-00-00 This research study focuses on the drive to operationalize capital and service costs favoring non-conventional business models (MES and MVS) in Poland over traditional capital-intensive purchasing and service models. The study also features a detailed elaboration on the legacy of public-private partnerships (PPP), framework agreement case studies, market opportunity, market size and penetration analysis coupled with merger and acquisitions and the competitive landscape, in addition to growth opportunities. Frost & Sullivan's Definition on MES and MVS for Poland market: Managed Equipment Services (MES): This is a bundled solution that includes the purchase of new equipment in addition to basic maintenance and support, technology management, planning and potentially a number of more advanced value-adding services. The bundle is usually financed by the customer through operational expenditure and typically extends, at a minimum, throughout the life-cycle of the equipment (7+ years). Multi-Vendor Services (MVS): This is a vendor-neutral offering combining basic and more advanced services, such as repair and maintenance services in addition to replacement planning (small components in imaging systems) for multi-modality imaging fleet. The MVS does not include purchase of new equipment like in MES. The MVS provider can be the OEM of part of the equipment, or a third-party company, and act as a single source for service, working in line with in-house resources at the imaging provider site. Key Market Dynamics: The high cost sensitivity among Poland public healthcare providers and their lasting limited access to capital funding are the key motivation for their consideration to adopt new purchasing and service models for capital imaging equipment. Recent hospital infrastructure growth in Poland is expected to set high expectations in implementing the public-private partnership (PPP) models in Poland. In line with current global PPP trends, Poland shows a great adaption with PPP models and the recent research sates, by the end of 2016 all hospitals in Poland must be brought in line with European Union (EU) technical and sanitary standards. Poland is currently undergoing a transition phase due to the structural changes in legislative process to reform its health care system. The current PIS government has commenced a remodeling platform of the Polish health care delivery system which favors in establishing the national public hospital networks, thereby discarding the previous government s efforts to privatize the hospitals. Moving forward, the number of existing and planned public-private partnerships (PPP) for greenfield hospital build may offer a strong basis for new capital purchasing models of imaging technology.Mergers and Acquisition (M&A) activity is allowing certain vendors to scale-up their capabilities and re-position their offerings in the Poland market and to bid competitively for tenders involving fleet-wide and multi-modality management service contracts. Fri, 16 Feb 2018 00:00:00 +0000 Role of Artificial Intelligence in Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-1A-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-1A-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) provides insights on the role of artificial intelligence in drug discovery and development. The service encompasses innovations across reverse engineering platforms, Big Data analytics, deep learning, and machine learning platforms for drug discovery and development. Additionally, this TOE encompasses developments across drug repurposing technologies and drug discovery trends. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Big Data, drug discovery, artificial intelligence, deep learning, RNA splicing, small molecules, machine learning, drug repurposing, cloud computing, reverse engineering Fri, 9 Feb 2018 00:00:00 +0000 Plasmid DNA Technology Platforms Transforming Gene Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6C-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6C-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across plasmid DNA and DNA vaccine technologies. The role of plasmid DNA manufacturing in the pharmaceutical industry, especially in cancer immunotherapy, is illustrated across industry profiles and notable innovations in the field. The corresponding clinical trial scenario for DNA vaccines is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Plasmid DNA, adjuvant technology, DNA vaccine, DNA product manufacturing, plasmid DNA biomanufacturing, cancer immunotherapy, targeted immune response Fri, 9 Feb 2018 00:00:00 +0000 Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1EE-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1EE-01-00-00-00 The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and recent favorable regulatory reforms (China to accept overseas trial data; Indian government allowing? academic institutions to take Drug Controller General of India (DCGI) permission) are expected to drive the demand for clinical trial IT solutions from 2017 to 2020. Clinical trial data management (CTDM) and emerging eClinical solutions comprising electronic data capture (EDC), clinical data management systems (CDMS), clinical trial management systems (CTMS), randomization and trial supply management systems (RTMS), electronic clinical outcome assessment (eCOA), trail planning and safety solutions, clinical data integration platforms, and clinical analytics platform have the largest market shares in the total clinical trial IT solutions, and are estimated to touch $4,051.6 million in 2020. Digital transformation is leading the clinical trial industry towards a data centric approach. The increasing volume and veracity of data that can be leveraged beyond traditional clinical data sets requires clinical trial IT systems to shift from fragmented application-centric IT systems to unified data-centric solutions. Furthermore, the rising demand for quality data and novel endpoints demands CTDM solutions to migrate from point solutions that sit in silos to integrated eClinical solutions that provide a single source of truth, optimize costs by eliminating duplicate data entry, and reduce on-site verification and source data verification rate (SDVR). This involves an evolving vendor ecosystem of modular, cloud-based eClinical solutions with intuitive user interface that is capable of integrating all possible study and eSource data to enhance clinical trial digital workflows and reduce data management cost and time.--BEGIN PROMO--

Research Scope
The research service analyzes the top four growth opportunities in the global CTDM and emerging eClinical solutions. It also evaluates and discusses market projections, key trends, technology life cycle (adoption rate vs maturity), key implementation benefits, and challenges of top four CTDM and emerging eClinical solutions. Finally, it provides industry best practices, live case studies, cost benefit analysis, and strategic imperatives (call to action) for key clinical trial industry stakeholders such as pharma sponsors, CRO, sites, and technology providers.

Key Issues Addressed

  • What are the key trends and growth opportunities that can be derived from the emerging digitally-led clinical trials operating models?
  • Which technologies and IT systems (EDC, eSource, eCOA, RTSM) will have the strongest potential to optimize clinical workflows?
  • What is the technology lifecycle for select clinical trials IT solutions (current adoption and future growth rates)?
  • What are the gaps and inefficiencies in current CTDM workflows and how can these be filled by emerging clinical IT solutions?
  • What does the new ecosystem of unified clinical IT systems/ eClinial solution providers look like?
  • What are the key challenges while implementing these digital solutions across the clinical development value chain?
Tue, 6 Feb 2018 00:00:00 +0000
Advancements in Neurology, Disease Diagnostics, Chemical Separation, and Driver Assistance Systems http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-6B-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-6B-00-00 This edition of the Inside R&D TOE profiles innovations associated with neurology, disease diagnostics, and driver assistance systems . The TOE also focuses on selective chemical separation and novel liquid biopsy test for eight common types of cancer. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Liquid biopsy, driver assistance systems, impulsive behavior, selective chemical separation Fri, 2 Feb 2018 00:00:00 +0000 Recent Collaborations in Biotech http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6B-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6B-00-00 This edition of the Genetic Technology TOE depicts provides insights on recent collaborative advancements across the global biotech landscape. The TOE also provides additional analysis of CRSIPR-based clinical trials. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Convergent bioscience, immuno-oncology, therapeutic antibodies, gene editing, CRISPR, viral vector Fri, 2 Feb 2018 00:00:00 +0000 Femtech Time for a Digital Revolution in the Women s Health Market http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298294020 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298294020 Thu, 1 Feb 2018 03:59:39 +0000 Will Technology in Healthcare Make the Rich Healthier and the Poor Sicker? http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298280845 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298280845 Tue, 30 Jan 2018 05:49:02 +0000 THE H IN HEALTHCARE OF 2025 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298278087 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298278087 Mon, 29 Jan 2018 06:14:42 +0000 Innovations in At-home Skin Imaging, Fetal CHD Imaging, Breast Biopsy Imaging, and Cloud-based Image Analysis and Managment Solutions http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1C-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1C-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in medical imaging and diagnostics industry. Some of the profiles covered include featuring at-home skin imaging tool, imaging for fetal CHD, real-time breast biopsy imaging, cloud-based image management and surgical planning, PET imaging tracer for tau pathologies, stain-free digital pathology system and cloud-based artificial intelligence solutions. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: At-home skin imaging, real-time breast biopsy imaging, cloud-based artificial intelligence, PET imaging tracer, stain-free pathology Fri, 26 Jan 2018 00:00:00 +0000 Diagnostic and Precision Medicine Advances Transforming the Biotech Landscape http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6A-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-6A-00-00 This edition of the Genetic Technology TOE provides insights on recent developments and innovations in genetic diagnostics and precision medicine. The service also provides clinical trial analysis for utomilumab. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genetic diagnostics, hereditary disease, precision medicine, blockchain, CAR-T cell, bispecific antibody, humanized antibody, 4-1BB agonist Fri, 26 Jan 2018 00:00:00 +0000 Advancements in Lasers, Power Generation, Diabetes Treatment, and AI-based Traffic Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-69-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-69-00-00 This edition of the Inside R&D TechVision Opportunity Engine (TOE) depicts developments associated with laser light in dental treatment, rare earth element recovery, and diabetes treatment. The TOE also focuses on advancements in syngas-based fuel production from coal and AI-based traffic management solution. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Rare earth material, laser dental treatment, syngas, AI, smart microneedle patch Fri, 19 Jan 2018 00:00:00 +0000 Blockchain Technology Empowering Genetics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-69-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-69-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across blockchain technology. The TOEs emphasizes how leading edge computing science is impacting genetics through cryptocurrency and blockchain technology. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Computing science, genetics, genomics, blockchain technology, cryptocurrency, cryptography, gene encryption, precision medicine, genomic metadata Fri, 19 Jan 2018 00:00:00 +0000 The Global Immuno-oncology Therapeutics Market Adoptive T-cell Therapies, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MC55-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MC55-01-00-00-00 Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done through activating and inhibiting signal pathways. Chimeric antigen receptor (CAR) T-cell therapy will change the way cancer is being treated. In the second half of 2017, the first two drugs in this new class of therapy were approved. Autologous T-cells that have been re-engineered can resist the immunosuppressive effects of tumors. The approved CAR-T therapies are directed against CD19 antigens and are approved to treat B-cell lymphoma and acute lymphocytic leukemia s, both B-cell mediated diseases. The process involved engineering autologous antigen presenting cells removed from the patient and run through a manufacturing process that takes 17 to 29 days depending on the drug before being infused back into the patient. There are over 200 clinical trials underway with CAR-T therapeutics, some trials in combination with already approved checkpoint inhibitors. The autologous therapies are patient-specific personalized treatments. The costs are staggering for these therapies, with treatments for the drug alone costing hundreds of thousands of dollars. That does not include the costs for other chemotherapies, hospital inpatient, and ICU care costs. Hospitals and clinics running the trials have experienced doctors and nurses that know how to handle this therapy. Expanding to new treatment arenas will be a challenge. Research advances in combination trials targeting more than one pathway may increase response rates over single targeted agents. If a combination product is produced by one company, it could be priced more competitively than targeted agents developed and marketed through a competitors alliance. New approaches to adoptive T-cell therapies remain a hurdle, but the ultimate goals of increasing overall survival are not insurmountable. Changes in standards-of-care may limit access to patients for clinical trials for these new therapies.--BEGIN PROMO--

Key Issues Addressed

  • What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
  • What products and indications will be launched in the next 7 years?
  • Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
  • What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of adoptive T-cell therapies?
  • What challenges do payors face related to the high cost of specialty therapeutics?
Fri, 19 Jan 2018 00:00:00 +0000
Innovations in Novel Stent Design, Diabetic Foot Ulcer Management, Automated Blood Glucose Monitoring, and PoC Breath Analyzer http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-19-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-19-00-00 The latest edition of Medical Device TOE profiles innovations in diverse markets such as coronary stents, shockwave therapy for diabetic foot ulcer management, continuous blood glucose monitoring, patient engagement platform, and continuous intravenous line monitoring. These innovations have been traced from across the globe - Singapore, Canada, Israel, Ireland and the United States, and represent a spectrum of technology readiness - pre-commercialization, new product launch, regulatory approval and so on. This mixed bag of innovation profiles also spans the industry and academia research groups. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Coronary stent, biomaterials, connected health, patient engagement, diabetic foot ulcer, shockwave, advanced wound care Fri, 19 Jan 2018 00:00:00 +0000 Frost & Sullivan s 10 Healthcare Predictions for 2018 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298234028 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298234028 At the start of every year, Frost & Sullivan s Transformational Health team brainstorms top predictions for the healthcare space. Despite on-going political uncertainties and rising cost pressures, the global healthcare industry will register a stable growth rate in 2018 and will cross the $1.85 trillion mark in terms of manufacturer revenue. Fri, 12 Jan 2018 00:00:00 +0000 Biotech Advances for Disease Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-68-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-68-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across disease management. Role of oncolytic viruses and gut microbiome in cancer immunotherapy is profiled in the TOE. Also profiled are a recent partnership among pharmaceutical companies, US FDA Breakthrough Therapy Designation received by a drug used for cytomegalovirus (CMV) treatment in transplant patients. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Oncolytic viruses, cancer immunotherapy, gut microbiome, genetic diagnostics Fri, 12 Jan 2018 00:00:00 +0000 Advancements in Protein Targets Discovery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-19-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-19-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across new technologies enabling the discovery of novel protein targets. The service encompasses innovations enabling protein target discovery, complement system activation, allosteric protein modulation, protein therapeutics, and targeted antibody treatments. Additionally, this TOE provides analysis of clinical trial studies for protein therapies. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Protein therapies, target discovery, complement activation, antibody, allosteric modification, cancer therapy, transplant rejection, achondroplasia, blood clotting, protein target Fri, 12 Jan 2018 00:00:00 +0000 APAC Biosimilar Market, Forecast 2025 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9A3-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9A3-01-00-00-00 Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan s estimate, biologic drugs worth $70 $80 billion will lose exclusivity in the next 5 years globally and APAC s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, offer an attractive opportunity for drug development and commercialization. Moreover, these are generics-driven markets, providing a positive opportunity for biosimilars development and commercialization.--BEGIN PROMO--

Research Highlights

The launch of innovative production platforms will reduce the cost of biosimilar production, thus providing substantial price differentiation. In the next 4–5 years, two-thirds of the patent expiries would be in biosimilars and specialty segments such as bio-betters that have high profit margins.
High revenue-churning blockbuster drugs are set to lose their patent protection in APAC during the forecast period and biosimilars companies are proactive in filing applications for marketing rights. In the pharmaceuticals market, there is a shift towards higher-value biological therapies, biosimilars, and specialty segments, where there is less competition despite high profit margins. With several biological drugs expected to lose patents by 2020, this segment is expected to experience an annual growth rate of more than 30.0% by 2020. Many Asian companies have biosimilars molecules under development, such as LG Life Sciences, Samsung Bioepis, and Celtrion. Cipla has already launched the biosimilar version in India in 2013, followed by Intas Pharmaceuticals in March 2015. Samsung Bioepis has also received approval for its biosimilar in South Korea in September 2015 for entracept.

Key Features

The key objective of this research service is to help clients identify the major growth opportunities for biosimilars across therapeutic areas such as rheumatoid arthritis, cancer, and diabetes, and understand the key challenges in the space.

Key Issues Addressed

  • What is the current scenario of the biosimilars market in APAC, and how far will it grow?
  • What are the key factors driving the market, and what are the barriers that need to be resolved?
  • Which are the key market segments to look out for, and what are the key trends and regulatory aspects?
  • Who are the key market participants involved, and where do they stand?
  • What are the factors affecting the biosimilars market in the different regions of APAC, and how will these factors affect the market?
  • What is the future of the biosimilars market in Asia?
Wed, 10 Jan 2018 00:00:00 +0000
Patient Safety in Healthcare, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K200-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K200-01-00-00-00 The study is a comprehensive analysis of 30 most pressing patient safety adverse events affecting patients, care givers, and healthcare organizations across the globe. The study measures the current and forecast country-wise cost impact, number of incidences, and mortality of individual adverse events. It goes on to list the top adverse events, increasingly capturing care provider mind shares, current investment trends and forecast stakeholder interests. It also analyses the current competitive environment, most impactful vendor solutions addressing the top patient safety issues and their future market potential. The study also highlights some of the most innovative and promising solutions capable of disrupting the market as well as convergence of new technologies entering the field. It finally concludes with pointing out the top 5 most compelling future growth opportunities, key strategies for growth and implementation challenges.--BEGIN PROMO--

Research Highlights

Frost & Sullivan estimates that the various adverse events put an additional cost burden of $317.9 billion on hospitals across the US and Western Europe, adversely affecting 91.8 million patients and leading to 1.95 million deaths in 2016. The cost burden is expected to increase at a CAGR of 3.2% to reach $383.7 billion by 2022.

Key Features

The various adverse events are segmented across four categories, namely

  • Patient Care Management (medication safety, wrong patient/ site/ indication (WPSI) events, patient falls, pressure ulcers, antibiotic resistance, patient handoff safety, maternal death and diagnostic safety);
  • Health IT Management (EHR/ EMR Safety, alarm fatigue, lack of patient engagement, hospital outcomes data transparency, protected health information (PHI) compromise, unnecessary emergency department (ED) admissions, and medical device cyber-security);
  • Surgical Care Management (CAUTI, vascular catheter infections, HAP/ VAP, venous thromboembolism, surgical site infections (SSI), sepsis, air embolism, foreign object post-surgery, off-label drug/ device usage); and
  • Environment and Workforce Management (burns/ thermal injuries, anesthesia safety, electrocution, healthcare worker (HCW) immunization, occupational physical safety hazards, and psychological health of HCW).

Research Benefits

The study contains the following key data points with respect to an adverse event—

  • Estimated mortality rate
  • Number of incidences in 2016, by region
  • Cost impact of each adverse event in 2016, by country
  • Estimated growth of cost impact till 2022, by country
  • Segment-wise average cost per adverse event, by country
  • Current and future assessment of each adverse event in terms of current degree of control on the issue and expected future stakeholder focus on combating the issue, by region
  • Estimation of market potential of each adverse event in terms of competitive intensity, effectiveness and expected future adoption potential of current vendor solutions, new innovative solutions addressing each issue and disruptive potential of the patient safety event
Tue, 9 Jan 2018 00:00:00 +0000
10 Future Healthcare Jobs to Watch http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298222025 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298222025 To say that healthcare is changing would be an understatement. Technology is transforming it, and some healthcare jobs may cease to exist in future. It is exciting to see what kind of new jobs will come about and what type of training will be required for the next-generation workforce. Tue, 9 Jan 2018 00:00:00 +0000 Recent Developments in Biotech http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-67-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-67-00-00 This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across molecular diagnostics. Topics embrace innovative molecular diagnostics platforms for cancer management and novel CAR-T cell platforms for the management of infectious diseases, as well as, recent registration for IPO (Initial Public Offering) and clinical trials. The corresponding clinical trials scenario is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Molecular diagnostics, cancer management, Initial Public Offering, CAR-T Cell Platform Fri, 5 Jan 2018 00:00:00 +0000 Movers & Shakers Interview with Mr. Richard Leftley - MicroEnsure http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298189884 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298189884 MicroEnsure is dedicated to creating, distributing and operating products that help uninsured people in emerging markets to mitigate the risks they face each day. By understanding our customers, providing innovative solutions and pushing ourselves to do everything better, our Company creates significant value for customers Wed, 3 Jan 2018 00:00:00 +0000 Global Healthcare Industry Outlook, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K227-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K227-01-00-00-00 In this research deliverable, Frost & Sullivan provides bold perspectives and predictions for the global healthcare industry in 2018. The markets covered include pharmaceuticals and biotech, in-vitro diagnostics, medical technologies, medical imaging, and healthcare IT. The analysis captures sectoral and regional trends and provides predictions for the upcoming year as organizations. This study provides guidance on where to find the greatest opportunities for expansion. Despite political uncertainties and cost pressures, the global healthcare industry will register a stable growth rate of 4.82% during 2018. With high spending on healthcare, prices of medical devices, consumables and drugs will continue to decline in the developed markets of the US and Western Europe. This would provide the impetus to change the paradigms of product development and geographic rollouts across high growth, emerging healthcare markets, especially the Asia-Pacific region. Furthermore, reimbursement for digital health will improve as managing efficiencies in healthcare delivery become ever more important. The unique confluence of emerging technologies and investment trends will make 2018 the year of technical breakthroughs with the adoption of popular digital health technology solutions such as artificial intelligence (AI), Internet of Medical Things (IoMT), Big Data analytics, and robotics across select healthcare segments.. In addition, cloud-based PaaS/SaaS platforms will be integral to any healthcare data monetization model. The transition of these technologies from ideation to actionable applications will drive growth opportunities across the globe.--BEGIN PROMO--

Key Features

Predictions for  the Total Healthcare Industry in 2018 include:

  • Product as a Service (XaaS) business models becoming the norm: the XaaS model will open new revenue streams driving future sustainability for the healthcare industry
  • Cloud emerging as core platform across multiple sectors as stakeholders demand cost efficiency: total healthcare cloud computing market for providers will cross the $5 billion mark in global revenues by 2018
  • Big Tech companies experiencing high rewards from their investments
  • Virtual and remote clinical trials adoption increasing with focus shifting to efficiency and patient-centricity
  • Robotics, ranging from automation to care delivery, progressing in provider utilities
  • Asia-Pacific countries taking the lead on ‘Smart’ hospital projects
  • Cyberattacks on the healthcare industry doubling, despite increased investments during 2018
  • Data insight-driven incentives impacting premiums and becoming standard for payer-corporate partnerships,  spurring wellness programs globallyKey

Key Issues Addressed

  • What are the top predictions for healthcare markets in 2018?
  • What market revenues and growth rates are anticipated for the global healthcare market?
  • What are the key projections and growth opportunities for major healthcare market segments?
  • What are the major macro and micro regional/country-level trends specific to the healthcare industry?
  • What are the key technologies and growth opportunities to watch for during 2018?
Wed, 3 Jan 2018 00:00:00 +0000
Emerging Sensor Technologies Transforming Medical Diagnostics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7FF-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7FF-01-00-00-00 TechVisions latest research service profiles innovations in sensing technologies and their impact on clinical diagnosis. The emergence of point of care (PoC) testing has necessitated compact, more portable testing kits, to replace laboratory testing. In the light of global epidemic outbreaks, there is also a greater need for high throughput testing to process infectious disease diagnosis faster. In view of these emerging trends, there is a greater dependence on faster, more accurate biochemical sensors. This research report focuses on implications for infectious diseases, cancer and lifestyle diseases such as cardiovascular diseases and Diabetes. Fri, 29 Dec 2017 00:00:00 +0000 Innovations in Transdermal Drug Delivery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D807-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D807-01-00-00-00 With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has several inherent limitations which can be overcome by technology innovations such as skin ablation (laser, radio frequency), electrical (iontophoresis and electroportation), mechanical (microneedle) methods. This research report focuses different technology innovations, key innovators in this space, industry trends, and impact across different therapeutic areas. Fri, 29 Dec 2017 00:00:00 +0000 Antimicrobial Technologies for Enhanced Consumer Health http://www.frost.com/prod/servlet/sublib/display-report.do?id=D80D-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D80D-01-00-00-00 Healthcare-associated infection (HAI) continues to be a significant global concern, hence there is growing research for developing new antimicrobial platforms that can significantly decrease the risk of microbial infections. While metallic ions continue to be one of the most potent antimicrobial technology platform, several new innovations across antimicrobial polymers, peptides and naturally sourced agents will lead the global consumer health landscape.Key opportunities for antimicrobial technologies will depend on the use of optimal combination of multiple microbicidal platforms for several consumer health applications. Fri, 29 Dec 2017 00:00:00 +0000 PROSTATE CANCER CARE http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298178151 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298178151 Technology has played multifaceted roles in transforming prostate cancer care. One of the most interesting amalgamations of technology and human behavioural science is the emergence of social media, which is playing a pivotal role in spreading awareness about prostate cancer. Fri, 29 Dec 2017 00:00:00 +0000 Technologies Impacting the Future of Korea http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7F8-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7F8-01-00-00-00 Korea is one of the world s biggest innovators in terms of research and development, patent activity, number of high-tech companies, value-added manufacturing, and researcher density per million of population. Korea s remarkable economic rise over the past decade can be attributed to the high amount of innovation and the rapid technology development. This report aims to outline broadly, those technologies that will disrupt the Korean innovation landscape in the near horizon. Ten technologies that we consider to be most impactful across a diverse technology areas have been profiled in this report, and they are Big Data technology 5G Smart Factories Rapid Charging Healthcare IT Digital Biomarkers Smart Water Management Electric Vehicles Lightweight Materials Bio-based Materials Thu, 28 Dec 2017 00:00:00 +0000 Healthcare Infrastructure in Nigeria, Key Opportunities 2017 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MCC5-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MCC5-01-00-00-00 Nigeria has the largest consumer base in Sub-Saharan region. A larger part of the population living in urban areas is a favorable indicator for market entry. Robust growth of around 7% for the past decade is threatened by macroeconomic challenges, particularly exchange-rate volatility and falling global oil prices that impact public-sector spending. Nigeria is the most populated country in the African continent with a population of approximately 186 million in 2016. The mixture of a large population, a swelling middle class with the capability to pay for services, an increasing demand for specialist facilities, and high-quality care which is evident from the large number of outbound medical tourists from the country. Despite the fact that a vast segment of Nigeria's population utilizes private health services and spends an enormous out-of-pocket share toward health expenditures, a sizable part of it is spent on low-quality services and products. Also, the unavailability of consistent and timely data on the Nigerian health sector for decision making pushes companies intending to invest in Nigeria to conduct a thorough market assessment for the specific products and services they plan to bring in. In order to harness the resources in both the public and the private healthcare sectors in Nigeria, the country has developed a National Policy on public private partnerships for health, aligned with the National Health Policy. The importance of public private partnerships is increasing due to the revitalization of the healthcare industry and the new hospital market, with the government often providing land for the project as well as security for investments. Nigeria suffers a heavy burden of infectious diseases, particularly malaria, and experiences frequent outbreaks of water-borne diseases such as cholera, which in some instances, requires hospitalization. Additionally, Nigeria has been witnessing an increase in the incidence of non-communicable diseases, which often lead to hospitalization if the condition is not well-managed. This increase in incidence of chronic and infectious diseases sets up an immense pressure to diagnose and treat faster and in a cost-effective manner. This makes requires a transformation of the healthcare infrastructure in Nigeria. This research intends to provide a clear indication of the current healthcare landscape in Nigeria as well as the level of development that currently exists in this market. The research service will highlight some key areas for investment in Nigeria, while many industries are still in a latent stage of development. In this way, the research service can begin to answer questions regarding the time horizon for future investment in key supporting industries such as private hospitals, health insurance, and more specialized devices, pharmaceuticals, and healthcare services. Wed, 27 Dec 2017 00:00:00 +0000 PACS and Integrated PACS Market Assessment in Brazil, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K23F-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K23F-01-00-00-00 Brazil currently spends over $80 million on PACS and integrated PACS systems, considering only the software involved. The overall penetration is increasing, although adoption varies significantly among geographical regions and by the size of institutions. While large-size hospitals and diagnostic centers are almost fully penetrated and are almost entirely in a replacement-only stage, ready for their second or even third-generation PACS solution, a good number of medium- and small-size healthcare institutions are still first-time purchasers. Between May and August 2017, Frost & Sullivan conducted primary research with 24 healthcare institutions, including hospitals and diagnostic centers, from different segments and sizes, spread in the various parts of Brazil. In-depth discussions were also conducted with all relevant PACS vendors in the Brazilian market, from multinational companies and established local players to new entrants. Our research found that only a little more than 15% of all PACS contracts across the country are already on a SaaS pay-per-use model. Although the market is mature enough to understand the benefits of this new model, legacy systems, cost of cloud storage, and concerns over data security are still issues that were highlighted by end-users interviewed for this study. However, the flexibility that this model provides, especially in terms of maintenance, dedicated local IT staff, and upfront investment needed will turn it into the new paradigm model in the medical image and information management systems industry. As a result, vendors will have to adjust their offer and delivery models, regardless of their niche focus. Brazil has been traditionally the biggest and most important market in Latin America (LATAM), setting the trends for the whole region. Leading market participants include Carestream, AGFA, GE, Phillips, and local companies such as Pixeon and MV. Our primary survey results indicate that the future market growth will still come from investments in new systems in the next five years, especially by medium- and small-size segments. This growth will be fueled by new business models offered notably by new local entrants that enable institutions under these segments to see value in the systems offered and the faster ROI. The current government initiative to promote 100% informatization in public hospitals and other public outpatient facilities, combined with the recent telehealth policy, makes the low-penetrated public system a potential market to be targeted. However, as the trend of adopting software-as-a-service (SaaS) model based on service level agreements (SLA) is still nascent in the public sector, providers willing to sell for public institutions may still need to also provide the hardware, aside from the software and consulting services. PACS is embedded in wider healthcare IT trends, such as patient engagement, multi-professional team collaboration. and cloud computing. In the future, growth opportunities in the imaging informatics space will have to consider these trends and how they affect the market dynamics and customers expectations: Enterprise PACS and VNA solutions will become the market standard, even for the small- and medium-size segments. Interoperability solutions to integrate different PACS and unified web-based PACS will progress from being a competitive advantage to a market standard. This is only a sample of insights that you can gain through our research.--BEGIN PROMO--

Key Issues Addressed

  • What is the market opportunity for PACS in Brazil?
  • Which customers segments represent the biggest opportunities?
  • What are the requirements of the different customer segments?
  • What are the different vendors’ solutions and strategies currently in place to address different needs and what are the unmet needs?
  • What are the technology advancements that are driving growth, and will fuel market growth in the next five years?
  • What is the long-term outlook for the PACS market, as new technology paradigms challenge the traditional PACS model?
Tue, 26 Dec 2017 00:00:00 +0000